Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus.

@article{Tew2010BaselineAP,
  title={Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus.},
  author={Gaik Wei Tew and Nusrat Rabbee and Kristen Wolslegel and H J Hsieh and John Monroe and Timothy W. Behrens and Paul G Brunetta and Mary E. Keir},
  journal={Lupus},
  year={2010},
  volume={19 2},
  pages={146-57}
}
B cells are thought to play a major role in the pathogenesis of systemic lupus erythematosus (SLE). Rituximab (RTX), a chimeric anti-CD20 mAb, effectively depletes CD20( +) peripheral B cells. Recent results from EXPLORER, a placebo-controlled trial of RTX in addition to aggressive prednisone and immunosuppressive therapy, showed similar levels of clinical benefit in patients with active extra-renal SLE despite effective B cell depletion. We performed further data analyses to determine whether… CONTINUE READING